Welcome to our dedicated page for KESTRA MED TECHNOLOGIES news (Ticker: KMTS), a resource for investors and traders seeking the latest updates and insights on KESTRA MED TECHNOLOGIES stock.
News for Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) focuses on its activities as a commercial-stage wearable medical device and digital healthcare company in cardiovascular care. Company announcements highlight developments related to its Cardiac Recovery System platform and ASSURE Wearable Cardioverter Defibrillator (ASSURE WCD), as well as financial performance and capital markets activity.
Investors and clinicians following KMTS news will see updates on clinical evidence, including communications about the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS), which Kestra describes as the largest prospective real-world study of wearable defibrillators to date. Press releases detail study design and key endpoints such as shock conversion success, inappropriate shock rates, wear time, and detection of additional arrhythmias in diverse cardiac recovery populations.
Kestra’s news flow also includes information on strategic collaborations, such as its agreement with Biobeat Technologies, Ltd. to integrate FDA-cleared, cuffless ambulatory blood pressure monitoring into the ASSURE WCD ecosystem. These items explain how additional diagnostic data, like 24-hour blood pressure measurements, may expand the clinical insights available for patients prescribed the wearable defibrillator.
Financial and corporate updates are another key component of KMTS coverage. The company issues press releases on quarterly financial results, preliminary revenue and margin trends, and public offerings of common shares. It also announces participation in major healthcare and investor conferences, including cardiology meetings and investment bank conferences, where management presents Kestra’s strategy and platform.
This news page aggregates these disclosures so readers can track Kestra’s clinical milestones, technology integrations, financial updates, and conference appearances in one place. For ongoing research into KMTS, users can review both operational announcements and regulatory communications as they are released.
Kestra Medical Technologies (Nasdaq: KMTS) announced primary results from ACE-PAS, the largest prospective real-world study of wearable defibrillators, presented at AHA Scientific Sessions 2025.
The study enrolled 21,612 patients and showed 100% successful conversion of VT/VF events versus the prespecified goal; an inappropriate-shock rate of 0.0065 per patient-month; 94% of patients had no false positive shock alarms; 2.6% experienced at least one life-threatening VT/VF; ASSURE detected 4.2% high-rate atrial fibrillation (35% newly diagnosed) and 0.3% severe bradycardia/asystole. Median wear time exceeded 23 hours/day, with one-third using the device beyond 90 days.
Kestra Medical Technologies (Nasdaq: KMTS) will present late-breaking results from the ACE-PAS trial at the American Heart Association Scientific Sessions 2025 on Nov 10, 2025 at 8:44 a.m. CT (Session 211–213).
ACE-PAS is a post-approval, real-world evaluation of the next-generation ASSURE wearable cardioverter defibrillator, enrolling more than 20,000 patients across the U.S., and is described as the largest prospective WCD study to date. Primary endpoints include overall shock conversion success and inappropriate shock rate; additional measures: first shock conversion success, median daily wear time, and false alarm rate.
Kestra will also host live demonstrations and an immersive in-booth experience at booth #4617 during AHA Nov 7–10, highlighting its Cardiac Recovery System and connected care tools.
Kestra Medical Technologies (Nasdaq: KMTS) will present at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 3:20 p.m. ET.
Investors and interested parties can watch a live webcast and later view a replay on the Kestra Medical Technologies investor relations website.
Kestra Medical Technologies (Nasdaq: KMTS) appointed Timothy Moran as Chief Business Officer, effective November 3, 2025. In the role Moran will lead business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management.
Moran brings over 25 years in medtech, most recently serving as president and CEO at Avertix Medical where he led a launch of a first‑to‑market implantable cardiac device, and previously as CEO of Motus GI Holdings. Management expects Moran to support the company’s commercial ramp, advance payor and provider partnerships, and accelerate adoption of the Cardiac Recovery System and ASSURE® WCD.
Kestra Medical Technologies (Nasdaq: KMTS) announced its participation in the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting in Minneapolis. The company will showcase its Cardiac Recovery System® (CRS) platform, featuring the ASSURE® Wearable Cardioverter Defibrillator at booth #920.
The CRS platform aims to enhance sudden cardiac death protection by combining protective measures with actionable insights during critical heart failure recovery phases. Visitors can experience hands-on demonstrations of the platform, which focuses on strengthening patient-provider connections and supporting vulnerable patients' recovery.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has appointed Dr. Elizabeth Kwo as an independent director to its board of directors. Dr. Kwo currently serves as Chief Commercial Officer of Everly Health and brings extensive experience in digital health platforms and data-driven care models.
Dr. Kwo's background includes roles as Deputy Chief Clinical Officer at Anthem, VP and GM of Provider Networks at American Well, and Entrepreneur in Residence at Harvard Medical School. She is board certified in preventive care and occupational medicine, holding degrees from Harvard Medical School (MD), Harvard School of Public Health (MPH), Harvard Business School (MBA), and Stanford University (BA).
Kestra Medical Technologies (Nasdaq: KMTS) reported strong Q1 FY26 financial results, with revenue reaching $19.4 million, a 52% increase year-over-year. The wearable medical device company saw significant growth with 4,205 prescriptions written for its ASSURE® system, up 51% from the previous year. Gross margin expanded to 45.7% from 32.9% year-over-year.
The company raised its FY26 revenue guidance to $88 million, representing 47% growth compared to FY25, up from previous guidance of $85 million. Despite strong top-line growth, Kestra reported a GAAP net loss of $25.8 million and held cash and equivalents of $201.2 million as of July 31, 2025.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has scheduled its first quarter fiscal 2026 earnings release for Thursday, September 11. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results.
Interested participants can access the live and archived webcast through the "Events" section of Kestra's investor relations website and are advised to register at least 10 minutes before the call begins.
Biobeat Technologies has appointed Raymond W. Cohen as Chairman of the Board of Directors. The company, which develops wearable medical devices, has received FDA clearance for its innovative patch device that monitors multiple physiological parameters including continuous cuff-less ambulatory blood pressure.
Cohen brings over 40 years of life science industry experience, notably as co-founder and CEO of Axonics, which was acquired by Boston Scientific for $3.7 billion in 2024. Under his leadership, Axonics generated over $1 billion in revenue within four years of commercial launch. Most recently, as chairman of SoniVie, he led its sale to Boston Scientific for $600 million in March 2025.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has been awarded the 2025 Top Workplaces Industry Award by Energage. The recognition is based on employee feedback through an engagement survey, highlighting Kestra's commitment to maintaining a people-first workplace culture.
CEO Brian Webster emphasized that this achievement reflects the team's dedication to their mission of advancing cardiac care through employee empowerment. The award positions Kestra as an employer of choice in the healthcare sector, with the company's workplace culture being specifically recognized for its focus on employee voice and engagement.